Narciclasine as well as other Amaryllidaceae Isocarbostyrils are Promising GTP-ase Targeting Agents against Brain Cancers

Medicinal Research Reviews

Volumn 33, Issue 2, 2013, Pages 439-455

  Van Goietsenoven, Gwendoline ^a   Mathieu, Véronique ^a   Lefranc, Florence ^a,b   Kornienko, Alexander ^c   Evidente, Antonio ^d   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c NEW MEXICO INSTITUTE OF MINING AND TECHNOLOGY   (United States)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Actin cytoskeleton; Amaryllidaceae isocarbostyril; Apoptosis resistance; Brain metastases; EEF1A; Glioma; GTPases; Narciclasine; Pancratistatin; RhoA

Indexed keywords

1 O ACETYLLYCORINE; 1,2 O,O' DIACETYL ALPHA DIHYDROLYCORINE; 1,2 O,O' DIACETYLLYCORINE; ACTIN; ALKALOID DERIVATIVE; AMARBELLISINE; AMARYLLIDACEAE ALKALOID; AMBELLINE; ANTINEOPLASTIC AGENT; CLIVONINE; CRININE; ELONGATION FACTOR 1ALPHA; GALANTHINE; GUANOSINE TRIPHOSPHATASE; HIPPEASTRINE; ISOCARBOSTYRIL DERIVATIVE; LYCORENINE; LYCORIN 2 ONE; LYCORINE; N METHYLLYCORINE; NARCICLASINE; NATURAL PRODUCT; NOBILISITINE A; NOBILISITINE B; NORPLUVINE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TAZETTINE; TETRAACETYLNARCICLASINE; UNCLASSIFIED DRUG; UNGEREMINE; UNINDEXED DRUG;

ACTIN FILAMENT; AMARYLLIDACEAE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CYTOSTASIS; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENDOTHELIUM CELL; FIBROBLAST; GLIOBLASTOMA; GLIOMA; GROWTH INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PLANT PHYSIOLOGY; PLASTID; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; COHORT STUDIES; CYTOTOXINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHENANTHRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 84873993446     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21253     Document Type: Article

References (67)

1. Ingrassia L, Lefranc F, Mathieu V, Darro F, Kiss R. Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising anti-tumor agents. Transl Oncol 2008;1:1-13.
2. Kornienko A, Evidente A. Chemistry, biology and medicinal potential of narciclasine and its congeners. Chem Rev 2008;108:1982-2014.
3. Riddle JM. Ancient and medieval chemotherapy for cancer. Isis 1985;76:319-330.
4. Ceriotti G. Narciclasine: An antimitotic substance from Narcissus bulbs. Nature 1967;213:595-596.
5. Ceriotti G. Activity of Narciclasine on mitosis of cells of the ascites sarcoma. Tumori 1967;53:437-445.
6. Carrasco L, Fresno M, Vazquez D. Narciclasine: An antitumour alkaloid which blocks peptide bond formation by eukaryotic ribosomes. FEBS Lett 1975;52:236-239.
7. Jimenez A, Sanchez L, Vazquez D. Location of resistance to the alkaloid narciclasine in the 60S ribosomal subunit. FEBS Lett 1975;55:53-56.
8. Jimenez A, Santos A, Alonso G, Vazquez D. Inhibitors of protein synthesis in eukaryotic cells comparative effects of some amaryllidaceae alkaloids. Biochem Biophys Acta 1976;425:342-348.
9. Evidente A, Kireev AS, Jenkins AR, Romero AE, Steelant WFA, Van Slambrouk S, Kornienko A. Biological evaluation of structurally diverse Amaryllidaceae alkaloids and their synthetic derivatives: Discovery of novel leads for anticancer drug design. Planta Med 2009;75:501-507.
10. Evidente A, Kornienko A. Anticancer evaluation of structurally diverse Amaryllidaceae alkaloids and their synthetic derivative. Phytochemistry Rev 2009;8:449-459.
11. Pettit GR, Pettit III GR, Backhaus Ra, Boyd MR, Meerow AW. Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod 1993;56:1682-1687.
12. Van Goietsenoven G, Andolfi A, Lallemand B, Cimmino A, Lamoral-Theys D, Gras T, Abou-Donia A, Dubois J, Lefranc F, Mathieu V, Kornienko A, Kiss R, Evidente A. Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. J Nat Prod 2010;73:1223-1227.
13. Lamoral-Theys D, Andolfi A, Van Goietsenoven, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyére C, Dubois J, Mathieu V, Kornienko A, Kiss R, Evidente A. Lycorine, the main phenanthridine Amaryllidaceae alkaloids, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: An investigation of structure-activity relationships and mechanistic insight. J Med Chem 2009;52:6244-6256.
14. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E, Kiss R. Structure-activity-relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae Isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 2009;52:1100-1114.
15. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, Kiss R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 2007;9:766-776.
16. McNulty J, Thorat A, Vurgun N, Nair JJ, Makaji E, Crankshaw DJ, Holloway AC, Pandey S. Human cytochrome P450 liability studies of trans-dihydronarciclasine: A readily available, potent, and selective cancer cell growth inhibitor. J Nat Prod 2011;74:106-108.
17. Pettit GR, Ducki S, Eastham SA, Melody N. Antineoplastic agents. 454. Synthesis of the strong cancer cell growth inhibitors trans-dihydronarciclasine and 7-deoxy-trans-dihydronarciclasine. J Nat Prod 2009;72:1279-1282.
18. Veronese FM, Ceriotti G, Keller G, Lora S, Carenza M. Controlled release of Narciclasine from poly(hema) matrices polymerized by a chemical initiator and by gamma irradiation. Radiat Phys Chem 1990;35:88-92.
19. Veronese FM, Ceriotti G, Caliceti P, Lora S, Carenza M. Slow release of Narciclasine from matrices obtained by radiation-induced polymerization. J Control Release 1991;16:291-298.
20. Beijnen JH, Flora KP, Halbert GW, Henrar REC, Slack JA. CRC/EORTC/NCI joint formulation working party - Experiences in the formulation of cytotoxic drugs. Br J Cancer 1995;72:210-218.
21. Torres-Labandeira JJ, Davignon P, Pitha J. Oversaturated solutions of drug in hydroxypropylcyclodextrin - Parenteral preparation of pancratistatin. J Pharm Sci 1991;80:384-386.
22. Pettit GR, Freeman S, Simpson MJ, Thompson MA, Boyd MR, Williams MD, Pettit GR. III, Doubek DL. Antineoplastic agents. 320. Synthesis of a practical pancratistatin Prodrug. Anti-Cancer Drug Des 1995;10:243-250.
23. Pettit GR, Orr B, Ducki S. Antineoplastic agents. 453. Synthesis of practical pancratistatin prodrugs. Anti-Cancer Drug Des 2000;15:389-395.
24. Pettit GR, Melody N, Simpson M, Thompson M, Herald DL, Knight JC. Antineoplastic agents. 500. Narcistatin J Nat Prod 2003;66:92-96.
25. Pettit GR, Melody N, Herald DL. Antineoplastic agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin. J Nat Prod 2004;67:322-327.
26. Pettit GR, Melody N. Antineoplastic agents. 527. Synthesis of 7-deoxynarcistatin, 7-deoxy-trans-dihydronarcistatin, and trans-dihydronarcistatin 1. J Nat Prod 2005;68:207-211.
27. Bibby MC, Holwell SE, Pettit GR. Anti-vascular and anti-tumor effects of the novel agent pancratistatin phosphate. Biological Basis for Antiangiogenic Therapy Conference. (Milan; Italy). Int J Biol Markers (meeting abstract) 1999; 14:278-326
28. Shnyder SD, Cooper PA, Millington NJ, Gill JH, Pettit GR, Bibby MC. Investigation of the efficacy and mechanism of action of pancratistatin 3, 4-cyclic phosphate. Clin Cancer Res. 2005;11:8971s-8971s.
29. Bi Y, Guo J, Zhang L, Wong Y. Changes in some enzymes of microbodies and plastid development in excised radish cotyledons: Effect of narciclasine. J Plant Physiol 2003;160:1041-1049.
30. Van Doorn WG, Sinz A, Tomassen MM. Daffodil flowers delay senescence in cut Iris flowers. Phytochemistry 2004;65:571-577.
31. Van Goietsenoven G, Hutton J, Becker JP, Lallemand B, Robert F, Lefranc F, Pirker C, Vandenbussche G, Van Antwerpen P, Evidente A, Berger W, Prévost M, Pelletier J, Kiss R, Kinzy TG, Kornienko A, Mathieu V. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J 2010;24:4575-4584.
32. Pettit GR, Gaddamidi V, Herald DL, Singh SB, Cragg GM, Schmidt JM, Boether FE, Williams M, Sagawa Y. Antineoplastic agents. 120. Pancratium littorale. J Nat Prod 1986;49:995-1002.
33. Kekre N, Griffin C, McNulty J, Pandey S. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemother Pharmacol 2005;56:29-38.
34. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 2005;10:619-630.
35. Griffin C, Hamm C, McNulty J, Pandey S. Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells. Cancer Cell Int 2010;10:6.
36. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomes: Special emphasis on cell migration and resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
37. Bonello TT, Stehn JR, Gunning PW. New approaches to targeting the actin cytoskeleton for chemotherapy. Future Med Chem 2009;1:1311-1331.
38. Williams C, Bryant A. Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma. Cochrane Database Syst Rev 2011;CD003911.
39. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011;8:244-250.
40. Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, Decaestecker C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol 2006;211:30-40.
41. Decaestecker C, Debeir O, Van Ham P, Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 2007;27:149-176.
42. Lefranc F, Sauvage S, Van Goietsenoven G, Mégalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, Kiss R. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther 2009;8:1739-1750.
43. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007;7:429-440.
44. Jaffe AB, Hall A. Rho GTPases: Biochemistry and biology. Annu Rev Cell Dev Biol 2005;21:247-269.
45. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 2000;275:3577-3582.
46. Yang F, Demma M, Warren V, Dharmawardhane S, Condeelis J. Identification of an actin-binding protein from Dictyostelium as elongation factor 1a. Nature 1990;347:494-496.
47. Murray JW, Edmonds BT, Liu G, Condeelis J. Bunding of actin filaments by elongation factor 1 alpha inhibits polymerization at filament ends. J Cell Biol 1996;135:1309-1321.
48. Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 2005;12:772-778.
49. Fritz G, Kaina B. Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006;6:1-14.
50. Konopka G, Bonni A. Signaling pathways regulating gliomagenesis. Curr Mol Med 2003;3:73-84.
51. Goldberg L, Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006;66:11709-11717.
52. Malchinkhuu E, Sato K, Maehama T, Mogi C, Tomura H, Ishiuchi S, Yoshimoto Y, Kurose H, Okajima F. S1p(2) receptors mediate inhibition of glioma cell migration through Rho signaling pathways independent of PTEN. Biochem Biophys Res Commun 2008;366:963-968.
53. Yan B, Chour HH, Peh BK, Lim C, Salto-Tellez M. RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett 2006;407:124-126.
54. Baldwin RM, Parolin DA, Lorimer IA. Regulation of glioblastoma cell invasion by PKCiota and RhoB. Oncogene 2008;27:3587-3595.
55. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E. Alphav-beta3/alphav-beta5 integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009;69:3308-3316.
56. Sasayama T, Nishihara M, Kondoh T, Hosoka K, Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 2009;125:1407-1413.
57. Poch E, Minambres R, Mocholi E, Ivorra C, Perez-Arago A, Guerri C, Perez-Roger I, Guasch RM. RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line. Exp Cell Res 2007;313:719-731.
58. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006;66:8492-8500.
59. Li X, Lee AY. Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through RhoGDIalpha-mediated inactivation of Rac1 GTPase. J Biol Chem 2010;285:32436-32445.
60. Yin JJ, Hu B, Jarzynka MJ, Feng H, Liu KW, Wu JY, Ma HI, Cheng SY. Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol 2009;11:779-789.
61. Oellers P, Schröer U, Senner V, Paulus W, Thanos S. ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia 2009;57:499-509.
62. Lefranc F, Facchini V, Kiss R. Pro-autophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007;12:1395-1403.
63. Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: A multicentre phase II trial. Lancet Oncol 2009;10:785-793.
64. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F. Combining Bevacizumab with temozolomide increases the anti-tumor efficacy of temozolomide in human glioblastoma orthotopic xenograft model. Neoplasia 2008;10:1383-1392.
65. Fidler I. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011;21:107-112.
66. Jenkinson M, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011;47:649-655.
67. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases. Cancer 2011;117:2505-2512